EX-99.1 2 v153131_ex99-1.htm EXHIBIT 99.1 Unassociated Document
Kewaunee Scientific Reports Record Results
Net Earnings for Year Increase 36%,
Sales Increase 16%

Exchange:
NASDAQ (KEQU)
Contact:
D. Michael Parker
      704/871-3290
 

STATESVILLE, N.C. June 24, 2009 -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported record sales, earnings, and order backlog for its fiscal year ended April 30, 2009.

Net  earnings for the year increased 36% to $4,247,000, or $1.66 per diluted share, up from net earnings of $3,134,000, or $1.23 per diluted share, in the prior year.  Earnings benefited from higher sales volume, lower manufacturing costs and improved operational efficiencies.

Sales for the year increased 16% to $103,978,000, up from sales of $89,510,000 in the prior year. Sales from domestic operations increased to $90,250,000, up 22.0% from the prior year. Sales from international operations were $13,728,000, down 13% from the prior year.  Incoming orders activity was strong throughout the year, as a healthy domestic laboratory furniture marketplace more than offset the impact of a soft Asian marketplace. The order backlog increased to a record $62.7 million at April 30, 2009, up from $60.7 million at January 31, 2009 and $58.7 million at April 30, 2008.

Net earnings for the fourth quarter were $920,000, or $0.36 per diluted share, up from net earnings of $446,000, or $0.17 per diluted share, in the prior year. Sales for the fourth quarter increased to $24,828,000, up 12% from sales of $22,116,000 in the same period of the prior year. Sales from domestic operations for the quarter were $22,954,000, up from sales of $18,015,000 in the same quarter of the prior year, while sales from international operations were $1,874,000, down from sales of $4,101,000 in the prior year.

The Company’s balance sheet remains strong. Working capital increased to $18.9 million at April 30, 2009, up from $15.9 million at the end of the prior year.  Cash on hand at the end of the year was $4.0 million, as compared to $4.3 million at the end of the prior year. Bank borrowings and capital lease obligations were $6.1 million at year-end, as compared to $5.0 million at the end of the prior year, and the debt-to-equity ratio was .23-to-1 at year-end, as compared to .19-to-1 at the end of the prior year.

“This past year was a rewarding, yet challenging year,” said William A. Shumaker, President and Chief Executive Officer. “Our programs and strategies over the past few years to make Kewaunee a stronger and more competitive company were put to the test. During the first half of the year, we were confronted with escalating prices for certain raw materials, particularly steel and epoxy resin, and higher energy and transportation costs. This was followed by the global economic slowdown in the second half of the year. Despite these and other challenges, year-over-year increases in sales and net earnings were achieved for each quarter of the year, and we continued to build our order backlog.


“Looking toward fiscal year 2010, we believe a number of factors have the Company well-positioned for another good year,” continued Mr. Shumaker. “A healthy domestic laboratory furniture marketplace, our record order backlog, and excellent performances by our factories are providing us strong momentum. The Asian laboratory furniture marketplace, which was soft the past year, is expected to improve and provide increased opportunities. The move to our new, modern plant in Bangalore, India, is now complete. This plant has full manufacturing capabilities which positions us to compete more broadly for additional projects in Asia and the Middle East.  Next year will also present a number of challenges. These include uncertainty as to when the global economic slowdown will end and higher pension costs for the Company due to losses in our pension investments portfolio.”
 
Kewaunee Scientific Corporation is a recognized leader in the design, manufacture, and installation of scientific and technical furniture. The Company's corporate headquarters and domestic manufacturing facilities are located in Statesville, North Carolina. The Company has subsidiaries in Singapore and Bangalore, India which serve the Asian and Middle East markets. Kewaunee Scientific's website is located at www.kewaunee.com.
 
Certain statements in this release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices.
 

Consolidated Statements of Operations
(in thousands, except per share data)
 
     
Three Months Ended
April 30
     
Years Ended
April 30
 
     
2009
     
2008
     
2009
     
2008
 
     
(Unaudited)
                 
                                 
Net sales
  $ 24,828     $ 22,116     $ 103,978     $ 89,510  
                                 
Cost of products sold
    19,759       17,579       82,605       70,338  
Gross profit
    5,069       4,537       21,373       19,172  
Operating expenses
    3,405       3,748       14,289       13,559  
Operating earnings
    1,664       789       7,084       5,613  
Other income (expense)
    8       49       (28 )     47  
Interest expense
    (49 )     8       (280 )     (294 )
                                 
Earnings before income taxes
    1,623       846       6,776       5,366  
Income tax expense
    669       342       2,264       1,733  
                                 
Earnings before minority interests
    954       504       4,512       3,633  
Minority interests in subsidiaries
    (34 )     (58 )     (265 )     (499 )
Net earnings
  $ 920     $ 446     $ 4,247     $ 3,134  
 
 
Net earnings per share
                       
           Basic
  $ 0.36     $ 0.17     $ 1.66     $ 1.24  
           Diluted
  $ 0.36     $ 0.17     $ 1.66     $ 1.23  
Weighted average number of common
                               
       shares outstanding (in thousands)
                               
           Basic
    2,556       2,551       2,555       2,530  
           Diluted
    2,556       2,577       2,561       2,557  


 

 

Condensed Consolidated Balance Sheets
(in thousands)
 
    April 30    
April 30
 
 
 
 2009
   
 2008
 
Assets
           
             
Cash and cash equivalents
  $ 3,559     $ 3,784  
Restricted cash
    456       480  
Receivables, less allowances
    24,526       20,087  
Inventories
    7,839       6,984  
Prepaid expenses and other current assets
    1,165       1,847  
                 
   Total current assets
    37,545       33,182  
Net property, plant and equipment
    11,369       11,825  
Other assets
    3,615       5,599  
Total Assets
  $ 52,529     $ 50,606  
                 
Liabilities and Stockholders’ Equity
               
                 
Short-term borrowings
  $ 5,720     $ 4,551  
Current obligations under capital leases
    220       323  
Accounts payable
    8,812       8,929  
Other current liabilities
    3,911       3,459  
   Total current liabilities
    18,663       17,262  
Other non-current liabilities
    6,913       6,397  
Total stockholders’ equity
    26,953       26,947  
Total Liabilities and Stockholders’ Equity
  $ 52,529     $ 50,606